6,678 trials
Hypertension · Brain Tumor · Epilepsy
Primary: The Primary Endpoint of This Trial is the Proportion of Patients Who Did Not Require Rescue Antihypertensive Medication to Maintain SBP Below 130 mmHg (i.e. Clevidipine…
Osteoarthritis
Primary: Change in Hemoglobin on Day 0 Compared to Preoperatively — -1.548; -1.458 g/dL
Colorectal Surgery
Primary: To Evaluate Rate of Anastomotic Leaks Related to the Use of the ColonRing™ Device, at 1 Month
HIV
Primary: Change in Flow-mediated Dilation (FMD) of the Brachial Artery — -0.67; -0.1 % change from baseline — p=0.67
HIV Infections
Primary: Plasma Viral Loads (HIV-1 RNA PCR) — 92.7; 88 percentage of subjects
HIV Infections
Primary: 24-hr LPV AUC — 142,160; 152140 ng*hr/mL
Relapsing-remitting Multiple Sclerosis
Primary: Percentage of the Sites Developing a Injection Site Reaction (ISR) Reported by Participants 24 Hours After Each Injection — 31; 37 Percentage of sites
Tetanus · Diphtheria · Pertussis
Primary: Number of Participants With Antibody Responses to Tetanus and Diphtheria Components Following Vaccination With Either Adacel® or BOOSTRIX® Vaccine — 172; 177; 196; 194…
HIV Infections
Primary: Proportion of Patient With Viral Load Less Than 400 Copies/mL — 89; 73 percentage
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
Type 2 Diabetes
Primary: HbA1c — 8.7; 8.7; 8.6; 8.4 percentage of gycosylated HbA1c — p=0.771
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Primary: Objective Response Rate (ORR) (Investigator) — 69.8; 30.2 Percentage of Participants
Social Phobia
Primary: Rates of Remission (LSAS≤30) After 12 Weeks of Randomized Treatment During Phase II, Among Phase I Non-responders — 17; 11; 10 participants
Ischemic Heart Disease
Primary: Epicardial Coronary Artery Endothelial Function (Adjusted) at Week 16 Comparing the Eplerenone Group to the Placebo Group — -1.2; -10.7 % change wk16-%change wk0…
Meningococcal Infection
Primary: Serum Bactericidal Activity Against MenC — 6786; 6278; 2061; 1746 GMTs